ESSA Pharma Inc

EPIX

0.201USD

0.000

Market hours （ET）Quotes delayed by 15 min

ESSA Pharma Inc's Score

Industry at a Glance

Industry Ranking

9 / 14

Overall Ranking

558 / 4699

Industry

Investment Holding Companies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

--

Current Rating

1.700

Target Price

+744.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ESSA Pharma Inc Highlights

StrengthsRisks

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 34.87M shares, decreasing 27.83% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 15.75.

There is no financial score for this company; the Investment Holding Companies industry's average is 7.05.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 7.13, which is lower than the Investment Holding Companies industry's average of 7.20. Its current P/E ratio is 0.00, which is NaN% below the recent high of 0.00 and +Inf% above the recent low of -3.39.

Score

Industry at a Glance

Previous score

7.13

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 9/14

No Data

There is no earnings forecast score for this company; the Investment Holding Companies industry's average is 8.25. The average price target for ESSA Pharma Inc is 1.70, with a high of 1.70 and a low of 1.70.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 5.47, which is lower than the Investment Holding Companies industry's average of 7.29.

Score

Industry at a Glance

Previous score

3.95

Change

1.52

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-09

The latest institutional shareholding proportion is 73.70%, representing a quarter-over-quarter increase of 1.35%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Opaleye Management Inc.

2.21M

--

BofA Global Research (US)

627.93K

-10.07%

Aldebaran Capital, LLC

578.94K

+1.69%

Aguja Capital GmbH

500.00K

--

Two Sigma Investments, LP

483.13K

-12.98%

DLD Asset Management, LP

314.97K

+71.50%

BNP Paribas Securities Corp. North America

271.19K

+15.21%

LMR Partners LLP

200.00K

--

J.P. Morgan Securities LLC

189.07K

+14.69%



1

2



There is no risk assessment score for the company; the Investment Holding Companies industry's average is 3.80. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

ESSA Pharma Inc

EPIX

2.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cannae Holdings Inc

CNNE

7.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Compass Diversified Holdings

CODI

6.71 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

HMR

6.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Blue Water Acquisition Corp III

BLUWU

5.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Universal Security Instruments Inc

UUU

5.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment